24/7 Market News Snapshot 18 March, 2025 – Indaptus Therapeutics, Inc. Common Stock (NASDAQ:INDP)

March 18, 2025

DENVER, Colo., 18 March, 2025 (247marketnews.com) – (Nasdaq:INDP) are discussed in this article.
Indaptus Therapeutics, Inc. (Nasdaq:INDP) is experiencing a notable surge in its stock, which opened at $0.845 and has risen to approximately $1.274, reflecting an increase of over 56.84%. This uptick in share price follows a previous close of $0.812 and signals growing investor confidence in the company’s innovative biopharmaceutical solutions. With a trading volume surpassing 1.05 million shares, market enthusiasm surrounding Indaptus is on the rise, indicating a pivotal moment for the company as it continues to advance its research initiatives.

In a significant development, Indaptus has initiated an expansion arm in its Phase 1b/2 clinical trial for Decoy20, a novel therapeutic designed to activate the immune system. This trial aims to evaluate the efficacy of Decoy20 in combination with BeiGene’s PD-1 checkpoint inhibitor, tislelizumab. The primary focus will be on assessing safety, optimizing dosages, and identifying early indicators of anti-tumor activity. Jeffrey Meckler, the CEO of Indaptus, expressed optimism about the trial, highlighting that preclinical data has consistently demonstrated synergistic effects between Decoy20 and checkpoint inhibitors. He noted the excitement surrounding the exploration of this combination in a clinical setting for the first time.

Participants in the trial will initially receive a week of Decoy20 monotherapy before transitioning to the combination treatment regimen. Patient safety remains paramount, and enrollment will initially proceed sequentially prior to unrestricted recruitment.

Indaptus is committed to leveraging its Decoy platform to improve cancer treatment outcomes, with the ongoing trial representing significant progress towards redefining therapeutic approaches in oncology. The company’s focus on innovative therapies demonstrates its dedication to engaging the immune response in the battle against malignancies, fostering hope for advancements in patient care.

Related news for (INDP)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.